Gastroenterologist Dr. Austin Chiang has about a decade of experience as a physician influencer on social media. During a conference in Chicago, he encouraged more providers to share their expertise on social media. By having a presence on these platforms, healthcare professionals demonstrate their commitment to meeting patients where they are, he said. By KATIE ADAMS As a gastroenterologist, Dr. Austin Chiang has witnessed plenty of patients get admitted to the hospital after taking unvetted medical advice they found on the Internet, he said Wednesday during an interview at Oliver Wyman’s Health Innovation Summit in Chicago. About 10 years ago, Dr. Chiang took to social media to address this issue by being a credible source for health information. At the time, many of his colleagues thought this was a waste of time — but he has since proved them wrong. He now has nearly 750,000 followers across his TikTok, YouTube, ...
New research led by Queen’s University Belfast has made a breakthrough in the field of microbiology, which could lead to the development of new treatments for people with compromised immune systems, such as those with cystic fibrosis. To conduct their study the researchers looked at the bacterium Achromobacter which can cause chronic lung infection and tissue damage in the airways. The study reveals how this bacterium overcomes the body’s immune defenses to multiply and continue to grow. The findings have been published in Cell Reports. Professor Miguel A. Valvano, Chair in Microbiology and Infectious Diseases at the Wellcome-Wolfson Institute for Experimental Medicine (WWIEM) at Queen’s University Belfast and lead researcher on the study, explains: “Achromobacter bacteria can cause chronic and potentially severe infections. However, until now, how this opportunistic bacterium interacts with the human immune system has been poorly understood. “These bacteria resist the action of multiple antibiotics; therefore, infection ...
by John Pinching The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact Ariceum Therapeutics, a company developing products for the treatment of specific cancers, has announced that the first patient has been dosed with its satoreotide therapy. The treatment targets extensive stage small cell lung cancer (ES-SCLC), while the research is taking place at the Murdoch University Health Center in Australia. Ariceum’s broader open label phase 1b trial will analyse the tolerability and safety of the ‘theranostic pair’ of somatostatin receptor antagonists, ga-satoreotide trizoxetan and lu-satoreotide tetraxetan, among patients with ES-SCLC. The central aim of the research is to establish a recommended phase 2 dose and schedule in due course. ‘Theranostics’ is the system of incorporating two paired drugs: the first, a diagnostic agent to identify cells that exhibit a particular biomarker, and the second, a therapeutic drug which subsequently acts on those cells. ...
GLP-1s — which lower blood sugar to help people lose weight — are taking the healthcare industry by storm and have several implications for digital health companies. This includes headwinds for established nutrition programs and the potential for the launch of new virtual weight loss startups, according to a PitchBook report published Friday. The PitchBook authors believe that because of the prevalence of obesity in the U.S., the impact of GLP-1s “will extend far beyond the drugmakers themselves.” So far, four GLP-1 agonists have FDA approval: Ozempic, Rybelsus, Wegovy and Mounjaro. Wegovy, however, is the only one indicated for weight loss, while the others are indicated for Type 2 diabetes. PitchBook listed the potential effect of weight loss drugs on several specific VC-backed digital health companies. For example, Ro and Noom may see new customers through their weight loss telehealth offerings. Form Health could see a rising adoption of their ...
Dive Brief The private equity firm Carlyle Group is leading the race to buy Medtronic’s connected patient monitoring and respiratory care operations, according to Reuters. Medtronic outlined plans to spin off the units almost one year ago. At the time, the company proposed creating a new connected care company, but the move reportedly led to interest from potential buyers including Siemens Healthineers and GE HealthCare. Now, with Medtronic nearing the end of its targeted window for completing a transaction, Reuters has reported that Carlyle has entered into exclusive negotiations to buy a majority stake in the two businesses at a valuation of more than $7 billion. Dive Insight Patient monitoring and respiratory interventions, part of Medtronic’s Medical Surgical portfolio, are among the slower-growing parts of the company. While neither business has the type of growth profile that Medtronic is targeting, they could be attractive to another company. According to Reuters, ...
By Jennifer Markarian Pictured: Illustration of students sitting at a table/iStock, undrey Although the biopharma industry tends to focus on high-skill workers with advanced science and engineering degrees, just over half of entry-level jobs in the U.S. life sciences require skills considered middle and lower level that could be filled by people with less than a four-year degree, according to a recent report on life sciences workforce trends by the Coalition of State Biosciences Institutes (CSBI), which promotes bioscience education and workforce development, and research group TEConomy Partners. “The share of middle-skills workers needed for entry-level positions in life sciences has held steady over the past decade,” Liisa Bozinovic, chair of CSBI, told BioSpace. Individuals with degrees from the U.S. network of two-year Advanced Technical Education biotechnology programs, which provide hands-on, industry-relevant training, have been successfully filling these positions, she added. Organizations Collaborate to Promote Biotech Education InnovATEBIO, a National ...
Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year. By FRANK VINLUAN A Travere Therapeutics drug that won speedy approval early this year for a rare autoimmune kidney disorder has failed to meet the key goal of its confirmatory study. Still, the biotech points to data trends favoring patients treated with its drug, Filspari, and it aims to seek full approval. But even if the FDA permits the drug to remain on the market, the disappointing trial results reported Thursday call into question the commercial prospects of a product once projected to become a blockbuster seller. Filspari was developed to treat immunoglobulin A nephropathy (IgAN), in which the buildup of antibodies in the kidneys damages these organs. The FDA awarded ...
Novo Nordisk has announced that it has entered into a partnership with Valo Health, worth up to $60m, to discover and develop new treatments for cardiometabolic diseases. The collaboration aims to utilise Valo’s Opal Computational Platform and real-world patient dataset, as well as its artificial intelligence (AI)-enabled small molecule discovery and its human tissue modelling platform, Biowire, to accelerate discovery and development. The Opal Computational Platform is an integrated, end-to-end drug discovery and development platform that is designed to enable a fully integrated and efficient approach for targeting and advancing candidates to regulatory approval. As part of the agreement, Valo will receive an upfront payment and a potential near-term milestone payment of $60m, as well as milestone payments for up to 11 programmes totalling up to $2.7 billion, plus research and development funding and potential royalty payments, said Novo Nordisk. Valo will enable the identification and validation of novel druggable ...
The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) have published a landscape review report, revealing that £1.1bn has been invested in UK research for rare diseases. The report findings aim to help focus areas for future funding and better target the needs of people with rare diseases. The review found that the NIHR and MRC accounted for almost £627m in funding across 698 studies between 2016 and 2021 for rare disease research. Comprised of 7,000 different types, rare diseases affect around 3.5 million people in the UK. The report revealed that motor neuron disease received the most funding in the portfolio, accounting for 8%, followed by Huntington’s disease (5%) and then preeclampsia (5%). Other diseases that received significant funding included cystic fibrosis (4%), frontotemporal dementia (4%) and idiopathic pulmonary (3%). Over five years, approximately £99.7m out of the nearly £627m of investment was ...
Report shows that if health service invests in community services hospital admissions will reduce Research commissioned by the NHS Confederation shows that the more the health service budget is invested in priming community services the more it decreases hospital admissions – bringing further savings across the wider NHS. Key figures show that for every £100 spent in the NHS community care sector, delivering care to patients closer to and in their own homes, there is a £131 return on investment in acute sector savings. This money would typically have been spent providing care to patients in hospitals and across acute services. The findings show how those areas of the country that spent less on community care in terms of population need have also seen – on average – higher levels of hospital and emergency activity, compared to those spending more. Indeed, those of the 42 integrated care systems that invested ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.